Prevalence of Bronchiectasis in COPD Patients

• Conditions: Bronchiectasis; Chronic Obstruct Airways Disease; Prognosis
• Interventions: Other: prevalence

• Registration Number: NCT04101448
• Lead Sponsor: Assiut University

Brief Summary

The identification of bronchiectasis in COPD has been defined as a different clinical COPD phenotype with greater symptomatic severity, more frequent chronic bronchial infection and exacerbations, and poor prognosis. A causal association has not yet been proven, but it is biologically plausible that COPD, and particularly the infective and exacerbator COPD phenotypes, could be the cause of bronchiectasis without any other known etiology, beyond any mere association or comorbidity.

Detailed Description

The relationship between bronchiectasis and COPD has generated several questions. Is there any real increased prevalence of bronchiectasis in patients with COPD? Does the presence of bronchiectasis have an impact on the clinical characteristics, prognosis, or response to treatment in COPD, to the extent that it can be considered a distinct clinical phenotype? Should bronchiectasis in patients with COPD be seen as merely a comorbidity, or as a consequence of the disease's natural history? Is there a causal relationship between COPD and bronchiectasis? If this is the case, what are the pathophysiological mechanisms responsible for this relationship? And, finally, what is the role of chronic bronchial infection and exacerbations in this relationship?

Study Timeline

• Status Verified: 2019-09
• Study First Submitted: 2019-09-22
• Study First Submitted QC: 2019-09-22
• Last Update Submitted: 2019-09-22
• Study First Posted: 2019-09-24
• Last Update Posted: 2019-09-24
• Study Start: 2019-09-30
• Primary Completion: 2020-09-01
• Study Completion: 2020-09-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• COPD patients based on GOLD 2019 criteria, stable or in exacerbation

Exclusion Criteria

• acute pneumonia within 2 months
• malignancy
• congenital bronchiectasis ( immobile cilia syndrome, Kartagnar syndrome).
• Pregnancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group A	prevalence	COPD patients with bronchiectasis
Group B	prevalence	COPD patients without bronchiectasis

Primary Outcome Measures

Name	Time	Method
Prevalence of Bronchiectasis in COPD	1 year	percentage of bronchiectasis diagnosed by CT chest in COPD patients

Secondary Outcome Measures

Name	Time	Method
impact of bronchiectasis on COPD intensive care admission	1 year	number of admissions in respiratory ICU and need for mechanical or non invasive ventilation
impact of bronchiectasis on COPD exacerbations	1 year	number of exacerbations treated in or out of hospitals
impact of bronchiectasis on COPD hospitalization	1 year	number of hospital admissions with acute exacerbations

Trial Locations

Locations (1)

AssiutU; 🇪🇬 Assiut, Egypt